Rosetta Genomics Cuts Q1 Loss

The firm recently set up a sales force in the US and anticipates the launch of its microRNA-based test for lung cancer in the coming months.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories